Indeed, in our study, we verified that targeting c-kit attenuated stemness of gefitinib resistant lung cancer cells and sensitized these cells to gefitinib treatment due to the persistent presence of EGFR 19del mutation. The gene discussed is KIT; the disease is lung carcinoma.